SCIENTIFIC PROGRAM – POSTER PRESENTATIONS

Poster presenters are requested to create their poster at the maximum size of 90cm (width) x 180cm (height). We suggest the size of 90cm (width) and 120cm (height). The organization will provide material to fix the poster at the board. Please see below the times of the poster sessions:

SESSION DATE TIME OF THE SESSION TIME OF PRESENTATION PLACE
Poster Session 1 April 26th, 2016 8:00 am – 12:30 pm 10:10am – 10:40am Poster Area
Poster Session 2 April 26th, 2016 1:00 pm – 5:30 pm 3:30 pm – 4:00 pm Poster Area
Poster Session 3 April 27th, 2016 8:00 am – 12:30 pm 10:10am – 10:40am Poster Area
Poster Session 4 April 27th, 2016 1:00 pm – 5:30 pm 3:30 pm – 4:00 pm Poster Area
Poster Session 5 April 28th, 2016 8:00 am – 12:30 pm 10:10am – 10:40am Poster Area
Poster Session 6 April 28th, 2016 8:00 am – 12:30 pm 10:10am – 10:40am Pampas Room
ABSTRACT CODE TITLE THEME PRESENTATION BOARD
POSTER SESSION 1
Date: April 26th / Place: POSTER AREA
Time of the session: 8:00 am – 12:30 pm / Time of the presentation: 10:15am – 10:40am
01 36 MICRORNA-9 PROMOTES PROLIFERATION OF LEUKEMIA CELLS IN ADULT CD34 POSITIVE ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE BY DOWN-REGULATION OF HES1 LEUKEMIA 60
02 184 MOLECULAR ANALYSIS OF FUSION GENES ASSOCIATED WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN PEDIATRIC PATIENTS IN PARÁ STATE, BRAZIL LEUKEMIA 61
03 223 HLA-A, -B -DRB1 ALLELE AND HAPLOTYPE FREQUENCIES IN BRAZILIAN BONE MARROW DONOR VOLUNTEERS FROM THE NORTH AND SOUTHEASTERN REGIONS LEUKEMIA 62
04 295 GENOMIC PROFILE OF PATIENTS WITH TRIPLE NEGATIVE (JAK2, CALR AND MPL) ESSENTIAL THROMBOCYTHEMIA AND PRIMARY MYELOFIBROSIS LEUKEMIA 63
05 298 THE PRESENCE OF ASXL1 MUTATIONS AS WELL AS A TOTAL NUMBER OF MYELOID DRIVER MUTATIONS HIGHER THAN TWO IS STRONGLY ASSOCIATED WITH THE DIAGNOSIS OF PRIMARY MYELOFIBROSIS AS OPPOSED TO ESSENTIAL THROMBOCYTHEMIA LEUKEMIA 64
06 318 PGEMOX/GELOX REGIMEN IS SUPERIOR TO NON-PGEMOX/GELOX REGIMENS IN THE TREATMENT OF PATIENTS WITH STAGE IE/IIE EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA: A MULTICENTER RETROSPECTIVE STUDY IN A COHORT OF 599 PATIENTS LEUKEMIA 65
07 356 TAFRO SYNDROME – FIRST CASE REPORTED IN LATIN AMERICA LEUKEMIA 66
08 357 CLONAL T CELL LARGE GRANULAR LYMPHOCYTE EXPANSION FOLLOWING HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN A PATIENT WITH HODGKIN LYMPHOMA – A CASE REPORT LEUKEMIA 67
09 361 NEW RISK FACTORS AND NEW TENDENCY FOR CENTRAL NERVOUS SYSTEM RELAPSE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA LEUKEMIA 68
10 539 EWING SARCOMA VS M7 ACUTE MYELOID LEUKEMIA: A SINGLE DISEASE OR COEXISTENCE OF TWO DIFFERENT DISEASES LEUKEMIA 69
11 588 BLOOD-BORNE DENGUE VIRUS: SEVERE DENGUE CASE REPORT IN A HEMATOPOIETIC STEM CELL RECIPIENT AND REVIEW LEUKEMIA 70
12 662 THE USE OF HEPARIN PRIME FOLLOWED BY ACID-CITRATE-DEXTROSE-ADENINE (ACD-A) FOR EXTRACORPOREAL PHOTOPHERESIS (ECP) USING THE CELLEX ® INSTRUMENT. LEUKEMIA 71
POSTER SESSION 2
Date: April 26th / Place: POSTER AREA
Time of the session: 1:00 pm – 5:30 pm / Time of the presentation: 3:30 pm – 4:00 pm
13 26 NOMOGRAMS TO ESTIMATE LONG-TERM OVERALL SURVIVAL AND BREAST CANCER-SPECIFIC SURVIVAL OF PATIENTS WITH LUMINAL BREAST CANCER BREAST 01
14 02
15 33 DIFFERENT PATTERNS IN THE PROGNOSTIC VALUE OF TUMOR SIZE FOR BREAST CANCER-SPECIFIC SURVIVAL STRATIFIED BY JOINT HORMONE RECEPTOR STATUS IN A SEER POPULATION-BASED ANALYSIS BREAST 03
16 43 PACLITAXEL AND PLATINUM IS FAVOR THAN ANTHRACYCLINES FOR PATIENTS WITH HER2 NEGATIVE BREAST CANCER BREAST 04
17 44 PREDICTORS FOR THE PATHOLOGICAL COMPLETE RESPONSE OF AXILLARY LYMPH NODE METASTASIS IN PATHOLOGICALLY PROVEN NODE POSITIVE BREAST CANCER PATIENTS BREAST 05
18 47 CLINICAL PATHOLOGIC CHARACTERISTICS OF MUCINOUS BREAST CANCER: A RETROSPECTIVE ANALYSIS OF 10-YEAR STUDY BREAST 06
19 67 IN SEARCH OF THE OPTIMAL TIMING OF BREAST RECONSTRUCTION IN THE CONTEXT OF IRRADIATION: A CONSECUTIVE 370 PEDICLED TRAM/DIEP FLAPS PERFORMED IN A SINGLE CENTER BREAST 07
20 75 GENETIC EVALUATION OF BRCA1 ASSOCIATED A COMPLEX GENES WITH TRIPLE-NEGATIVE BREAST CANCER SUSCEPTIBILITY IN CHINESE WOMEN BREAST 08
21 113 CLINICOPATHOLOGICAL CHARACTERISTICS AND SURVIVAL OUTCOMES OF INVASIVE PAPILLARY CARCINOMA OF BREAST: A SEER POPULATION-BASED STUDY BREAST 09
22 128 RISK FACTORS AND CLINICAL CHARACTERISTICS OF LOCO-REGIONAL RELAPSE IN LOCAL ADVANCED BREAST CANCER TREATED WITH NEOADJUVANT CHEMOTHERAPY FOLLOWING MASTECTOMY AND RADIOTHERAPY: A SINGLE-CENTER EXPERIENCE FOR NON-PATHOLOGICAL COMPLETE RESPONDERS BREAST 10
23 129 THE PHOSPHORYLATION-SPECIFIC ASSOCIATION OF STMN1 WITH GRP78 PROMOTES METASTASIS IN BREAST CANCER BREAST 11
24 190 ASPECTS OF IMAGE OF RADIAL SCAR / COMPLEX SCLEROSING LESION BREAST 12
25 191 SUPPORTING MRI IN SURGICAL PLANNING OF BREAST CANCER BREAST 13
26 192 THE ROLE OF MRI IN THE EVALUATION OF COMPROMISED SURGICAL MARGINS AND POSTOPERATIVE RESIDUAL DISEASE OF BREAST CANCER BREAST 14
27 218 LOW RATE OF POSITIVE MARGINS AND REEXCISION AFTER PARTIAL MASTECTOMY IN HIGHLY SELECTIVE BREAST CANCER PATIENTS:A CHINESE SINGLE-INSTITUTION EXPERIENCE BREAST 15
28 237 SELECTIVE SENTINEL LYMPH NODE AFTER NEOADJUVANT SYSTEMIC THERAPY ACCORDING TO ALTERATION OF 18FDG PET/CT UPTAKE IN AXILLA AND MOLECULAR SUBTYPE IN NODE POSITIVE BREAST CANCER: A PILOT STUDY BREAST 16
29 239 MIR-200C-3P MODULATES PACLITAXEL RESISTANCE IN BREAST CANCER CELLS PARTIALLY THROUGH AKT SIGNALING PATHWAY BREAST 17
30 250 METAPLASTIC BREAST CARCINOMA: WHAT THE ONCOLOGY TEAM SHOULD KNOW. BREAST 18
31 292 DIVERSE ROLE OF HOMEOSTATIC MUCOSA-ASSOCIATED CHEMOKINES IN BREAST CANCER BREAST 19
32 342 TUMOR SIZE IN BREAST INVASIVE DUCTAL CANCER AND THEIR RELATION TO CLINIC PATHOLOGIC CHARACTERISTICS, MOLECULAR MARKERS BREAST 20
33 366 RGD-CONJUGATED MESOPOROUS SILICA-ENCAPSULATED GOLD NANORODS ENHANCE THE SENSITIZATION OF TRIPLE-NEGATIVE BREAST CANCER TO MEGAVOLTAGE RADIATION THERAPY BREAST 21
34 368 ROLE OF BREAST MRI IN THE EVALUATION OF DUCTAL CARCINOMA IN SITU. BREAST 22
35 404 METAPLASTIC CARCINOMA OF THE BREAST: HOW DO THEY PRESENT AT IMAGING STUDIES? BREAST 23
36 429 EVALUATION OF SUSPICIOUS BREAST CALCIFICATIONS WITH POSITRON EMISSION MAMMOGRAPHY (PEM). BREAST 24
37 446 SINGLE INSTITUTION ASSESSMENT OF PATHOGENIC BRCA1 MUTATION IN TRIPLE NEGATIVE BREAST CANCER AND ITS ASSOCIATION WITH CLINICAL FEATURES AND TREATMENT RESPONSE BREAST 25
38 62 THE PREOPERATIVE SUVMAX FOR 18F-FDG UPTAKE PREDICTS SURVIVAL IN PATIENTS WITH COLORECTAL CANCER COLORECTAL 26
38 77 EXAMINING PLASMA MICRORNA MARKERS FOR COLORECTAL CANCER AT DIFFERENT STAGES COLORECTAL 27
40 141 INHIBIT THE FUNCTION OF SREBP1 POSSIBOLLY PROMOTE APOPTOSIS AND 5-FU SENSITIVITY OF COLORECTAL CANCER COLORECTAL 28
41 167 GAS1: EPITHELIAL-MESENCHYMAL TRANSITION AND WARBURG EFFECT INHIBITOR IN COLORECTAL CARCINOMA COLORECTAL 29
42 176 MIR-590-5P INHIBITS COLORECTAL CANCER ANGIOGENESIS AND METASTASIS BY REGULATING NUCLEAR FACTOR 90/VASCULAR ENDOTHELIAL GROWTH FACTOR AXIS COLORECTAL 30
43 254 RECTAL CANCER T STAGE: A COMPARATIVE STUDY TO EVALUATE PREDICTIVE ABILITY OF PET-CT AND MR COLORECTAL 31
44 293 TISSUE-ASSOCIATED BACTERIAL ALTERATIONS IN EARLY-STAGE RECTAL CARCINOMA PATIENTS REVEALED BY 16S RRNA COMMUNITY PROFILING COLORECTAL 32
45 304 A RANDOMIZED TRIAL OF LAPAROSCOPIC VERSUS OPEN SURGERY FOR COLORECTAL CANCER IN OPERATION RELATED COMPLICATIONS COLORECTAL 33
46 333 EXPRESSION OF FOXP3 AND PROGNOSTIC SIGNIFICANCE IN COLORECTAL CANCER COLORECTAL 34
47 351 HIGH ARG-1 EXPRESSION IS AN INDICATOR OF POOR PROGNOSIS IN COLORECTAL CANCER PATIENTS COLORECTAL 35
48 405 LOCOREGIONAL RESTAGING OF RECTAL CANCER BY MAGNETIC RESSONANTE IMAGING IN PATIENTS SUBMITTED TO NEOADJUVANT CHEMORADIORHERAPY: PICTORIAL ESSAY COLORECTAL 36
49 443 RAB5C ENHANCES RESISTANCE TO IONIZING RADIATION IN RECTAL CANCER COLORECTAL 37
50 548 CT-GUIDED PREOPERATIVE LOCALIZATION OF LIVER METASTASIS OF COLORECTAL CANCER USING METAL CLIPS – A CHEAPER AND MORE EFFICIENT WAY TO REDUCE MORBIDITY AND RESIDUAL LESIONS COLORECTAL 38
51 552 ASSOCIATION BETWEEN THE FINDINGS OF THE PROXIMAL AND DISTAL COLON DETECTED BY COLONOSCOPY: PERSPECTIVE OF THE USE OF SIGMOIDOSCOPY FOR COLORECTAL CANCER SCREENING COLORECTAL 39
52 554 SAFETY AND EFFICIENCY OF IMAGE-GUIDED CRYOABLATION IN UNRESECTABLE PELVIC RECURRENT COLORECTAL CANCER COLORECTAL 40
53 574 MUTATIONAL ANALYSIS OF KRAS AND BRAF IN SYNCHRONOUS AND MULTIPLE COLORECTAL LESIONS IN THE SAME PATIENT. COLORECTAL 41
54 599 REALISTIC SIMULATION USING HIGH FIDELITY MANIKIN IN POST OPERATIVE STATE OF RECTAL SIGMOIDECTOMY: AN EVIDENCE BASED PRACTICE INTEGRATING TEACHINGS TO CLINICAL PICTURE OF COMPLICATIONS COLORECTAL 42
55 651 CURCUMIN INHIBITS TUMOR EPITHELIAL-MESENCHYMAL TRANSITION (EMT) VIA DOWN-REGULATING WNT SIGNALING PATHWAY THROUGH UP-REGULATING NKD2 EXPRESSING IN COLON CANCER CELL COLORECTAL 43
56 28 DOWN-REGULATION OF CDKN3 INHIBITED PROSTATE CANCER PROLIFERATION IN VITRO AND IN VIVO VIA REGULATING CELL CYCLE AND DNA REPLICATION SIGNALING GENITOURINARY CANCERS 44
57 50 PATIENTS CHARACTERISTICS AND TREATMENT OUTCOME OF ORGAN CONFINED PROSTATE CANCER : KHCC EXPERIENCE GENITOURINARY CANCERS 45
58 53 CARDIAC COMORBIDITIES IN EARLY STAGE PROSTATE CANCER IN ACTIVE SURVEILLANCE GENITOURINARY CANCERS 46
59 97 GENETIC VARIANTS OF THE CYP1B1 GENE AS PREDICTORS OF BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY IN LOCALIZED PROSTATE CANCER PATIENTS GENITOURINARY CANCERS 48
60 258 COMPARISON OF APPARENT DIFFUSION COEFFICIENT VALUES BETWEEN NORMAL PROSTATIC TISSUE AND CLINICALLY SIGNIFICANT PROSTATE CANCER WITH DIFFERENT GLEASON SCORES IN PATIENTS SUBMITTED TO RADICAL PROSTATECTOMY GENITOURINARY CANCERS 49
61 259 PROSTATIC TUMORS BEYOND ADENOCARCINOMAS ON MULTIPARAMETRIC MRI GENITOURINARY CANCERS 50
62 320 MR GUIDED PROSTATE BIOPSY – INITIAL EXPERIENCE AT BANNER MD ANDERSON CANCER CENTER GENITOURINARY CANCERS 51
63 373 INCREMENTAL DIAGNOSTIC VALUE OF US-MRI TARGETED PROSTATIC BIOPSY VERSUS RANDOM BIOPSY: A PROSPECTIVE STUDY GENITOURINARY CANCERS 52
64 390 IMPACT OF PATHOLOGY REVIEW FOR DECISION THERAPY IN A MULTI-DISCIPLINARY CLINIC OF LOCALIZED PROSTATE CANCER GENITOURINARY CANCERS 53
65 400 CONTRAST-INDUCED NEPHROPATHY IN PATIENTS WITH CANCER WHO HAVE A SINGLE KIDNEY SUBMITTED TO COMPUTED TOMOGRAPHY, BEFORE AND AFTER INJECTION OF CONTRAST MEDIA IODINATED GENITOURINARY CANCERS 54
66 415 NADIR PSA ALONE OR IN COMBINATION WITH BASELINE PSA IMPROVES PREDICTION OF TREATMENT OUTCOME IN INTERMEDIATE AND HIGH RISK LOCALIZED PROSTATE CANCER PATIENTS TREATED BY DEFINITIVE EXTERNAL BEAM RADIOTHERAPY WITH ANDROGEN DEPRIVATION. GENITOURINARY CANCERS 55
67 474 INDICATIONS OF MAGNETIC RESONANCE IMAGING IN PROSTATE CANCER. GENITOURINARY CANCERS 56
68 621 GIANT ADRENAL CARCINOMA ASSOCIATED WITH VENA CAVA INVASION: CASE REPORT GENITOURINARY CANCERS 57
69 58
70 260 THE VALIDATION OF IMMUNOHISTOCHEMICAL TEST TO IDENTIFY BRAF MUTATION IN MELANOMAS MELANOMA 59
71 386 MICROMETASTASIS IN LYMPH NODE DIAGNOSED BY IMMUNOHISTOCHEMICAL EXAM ONLY IS REALLY SIGNIFICANT. CASE REPORT. MELANOMA 60
72 519 MOLECULAR PROFILING, INCLUDING TERT PROMOTER MUTATIONS, OF ACRAL LENTIGINOUS MELANOMAS MELANOMA 61
73 594 DIGITAL PATHOLOGY OF CUTANEOUS MALIGNANT MELANOMA BY SPATIAL TRANSCRIPTOMICS MELANOMA 62
POSTER SESSION 3
Date: April 27th / Place: POSTER AREA
Time of the session: 8:00am – 12:30pm / Time of the presentation: 10:10am – 10:40am
74 164 EFFECT OF RADIATION ON GLUCOSE METABOLISM IN BREAST CANCER CELLS CULTURED UNDER HYPOXIC CONDITION RADIATION ONCOLOGY 35
75 232 ANALYSIS OF INTER-FRACTION SETUP ERROR OF NASOPHARYNGEAL CARCINOMA TREATED WITH TOMOTHERAPY WITH MEGAVOLT COMPUTED TOMOGRAPHY RADIATION ONCOLOGY 36
76 240 A COMPARISON OF S1 AND S1 WITH NEDAPLATIN IN DEFINITIVE CHEMORADIATION IN UNRESECTABLE LOCALLY ADVANCED THORACIC ESOPHAGEAL CANCER PATIENTS RADIATION ONCOLOGY 37
77 521 EVALUATION OF CT GUIDED BIOPSY OF ABDOMINAL CAVITY LESIONS RADIATION ONCOLOGY 38
78 538 HOW TO DEVELOP A SUCCESSFUL RADIATION ONCOLOGY RESIDENCY PROGRAM IN A DEVELOPING COUNTRY WITH CONSTRAINED ECONOMY RADIATION ONCOLOGY 39
79 557 PERCUTANEOUS IMPLANTATION OF FIDUCIAL MARKERS FOR IMAGING GUIDED RADIATION ONCOLOGY 40
80 352 ESTABLISHMENT AND CHARACTERIZATION OF GENE KNOCKOUT TUMOR CELL LINES BY CRISPR/CAS9 NEW TOOLS IN MOLECULAR PATHOLOGY 41
81 440 SIGNER: SIGNATURE FINDER FOR MUTATIONAL PROCESSES IN CANCER GENOMES NEW TOOLS IN MOLECULAR PATHOLOGY 42
82 461 AUTOMATIC DETECTION AND CLASSIFICATION OF CELL NUCLEI IN IMMUNOHISTOCHEMICAL IMAGES WITH ESTROGENE RECEPTOR MARKER NEW TOOLS IN MOLECULAR PATHOLOGY 43
83 644 OCULAR SIDE EFFECTS WITH USE OF BIOLOGICAL THERAPY IN PATIENTS WITH CANCER NEW TOOLS IN MOLECULAR PATHOLOGY 44
84 80 PROJECT ECHO TELEMENTORING TO IMPROVE CERVICAL CANCER PREVENTION AND TREATMENT IN MEDICALLY UNDERSERVED AREAS GYNECOLOGIC CANCERS (INCLUDES CANCERS) 45
85 123 THE VOLUME-METABOLIC COMBINED PARAMETERS FROM 18F-FDG PET/CT MAY HELP PREDICT THE OUTCOMES OF CERVICAL CARCINOMA GYNECOLOGIC CANCERS (INCLUDES CANCERS) 46
86 194 CYTOLOGIC FINDINGS AND REPRODUCIBILITY OF CERVICAL-VAGINAL CYTOLOGIC ABNORMALITIES AFTER TREATMENT WITH PELVIC RADIOTHERAPY FOR CERVICAL CANCER. GYNECOLOGIC CANCERS (INCLUDES CANCERS) 47
87 269 A NEW CLINICALLY APPLICABLE AGE-SPECIFIC COMORBIDITY INDEX BASED ON SELF-REPORTED INFORMATION FOR PREOPERATIVE RISK ASSESSMENT OF OVARIAN CANCER PATIENTS GYNECOLOGIC CANCERS (INCLUDES CANCERS) 48
88 288 CORILAGIN, A PROMISING COMPLIMENTARY HERBAL AGENT FOR OVARIAN CANCER THERAPY GYNECOLOGIC CANCERS (INCLUDES CANCERS) 49
89 399 DIFFERENTIAL EXPRESSION OF MICRORNAS IN UTERINE LEIOMYOSARCOMA GYNECOLOGIC CANCERS (INCLUDES CANCERS) 50
90 417 BRAZILIAN PLATFORM FOR BIOPROSPECTING STUDIES OF NATURAL COMPOUNDS WITH ANTICANCER POTENTIAL IN PRE-CLINICAL PHASE: FIRST RESULTS GYNECOLOGIC CANCERS (INCLUDES CANCERS) 51
91 449 RNA INTERFERENCE-MEDIATED TARGETING OF CTNNB1 GENE EXPRESSION IN VULVA CARCINOMA CELLS CAUSES INCREASED TUMOR CELL INVASION AND MIGRATION GYNECOLOGIC CANCERS (INCLUDES CANCERS) 52
92 628 NEOADJUVANT CHEMOTHERAPY PLUS RADICAL HYSTERECTOMY VERSUS CHEMORADIATION FOR STAGE IB2 CERVICAL CANCER: THE INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS (INEN) – PERÚ EXPERIENCE GYNECOLOGIC CANCERS (INCLUDES CANCERS) 53
93 632 PROGNOSTIC FACTORS AND ROLE OF DEBULKING SURGERY IN CHEMOREFRACTORY OVARIAN GERM CELL MALIGNANCIES: A STUDY IN CHINESE PATIENTS GYNECOLOGIC CANCERS (INCLUDES CANCERS) 54
94 635 ABDOMINAL RADICAL TRACHELECTOMY (ART): WHAT’S THE ROLE IN FERTILITY-SPARING SURGERY FOR CERVICAL MALIGNANCIES? GYNECOLOGIC CANCERS (INCLUDES CANCERS) 55
95 246 POPULATION-BASED SCREENING OF AT-RISK WOMEN FOR HEREDITARY BREAST AND COLORECTAL CANCER IN BRAZIL USING A THREE-QUESTION QUESTIONNAIRE HEREDITARY TUMORS 56
96 283 GENETIC AND EPIGENETIC CHARACTERIZATION OF THE BRCA1 GENE IN BRAZILIAN WOMEN AT-RISK FOR HEREDITARY BREAST CANCER HEREDITARY TUMORS 57
97 354 SILENCING OF GENES MAPPED ON 7Q ARE CANDIDATES TO BE ASSOCIATED WITH MULTIPLE PRIMARY TUMORS INCLUDING TRIPLE NEGATIVE BREAST CANCER HEREDITARY TUMORS 58
98 416 A CORRELATION BETWEEN BRAZILIAN HISTORY AND THE R337H MUTATION IN TP53 GENE. HEREDITARY TUMORS 59
99 445 SEARCHING FOR NEW GENES ASSOCIATED TO HEREDITARY BREAST CANCER USING WHOLE EXOME SEQUENCING HEREDITARY TUMORS 60
100 487 TREATMENT OUTCOME OF NEUROFIBROMATOSIS TYPE 1 ASSOCIATED AND SPORADIC MALIGNANT PERIPHERAL NERVE SHEATH TUMOR HEREDITARY TUMORS 61
101 507 SEARCHING FOR NEW GENES ASSOCIATED TO HEREDITARY BREAST CANCER USING WHOLE EXOME SEQUENCING. HEREDITARY TUMORS 62
102 508 CANCER GENETIC RISK ASSESSMENT IN PEDIATRIC ONCOLOGY: RESULTS AND CHALLENGES OF A BRAZILIAN EXPERIENCE HEREDITARY TUMORS 63
103 55 EFFICACY ANALYSIS OF COMPLETE LAPAROSCOPIC RESECTION OF RECURRENT HEPATOCELLULAR CARCINOMA PERSONALIZED MEDICINE 64
104 195 INVESTIGATION OF OSTEOSARCOMA GENOMICS AND ITS IMPACT ON TARGETED THERAPY PERSONALIZED MEDICINE 65
105 227 FUNCTIONAL ROLE AND CLINICAL IMPACT OF KIT GNNK+ AND GNNK- ISOFORMS IN GLIOBLASTOMA PERSONALIZED MEDICINE 66
106 336 WHOLE GENOME SEQUENCING (WGS) OF BRAZILIAN MELANOMA PATIENTS AS PART OF THE INTERNATIONAL CANCER GENOME CONSORTIUM. PERSONALIZED MEDICINE 67
107 369 PROGNOSTIC VALUE OF DNA DAMAGE INDUCIBLE TRANSCRIPT 4 GENE (DDIT4) IN VARIOUS CANCERS: IN SILICO EVALUATION PERSONALIZED MEDICINE 68
108 409 PHENOTYPICAL AND MOLECULAR CHARACTERIZATION OF CELL CULTURES DERIVED FROM USUAL PENILE CARCINOMAS PERSONALIZED MEDICINE 69
109 448 INNOVATIVE CLINICAL TRIAL DESIGN AND IMPLEMENTATION AT MD ANDERSON CANCER CENTER PERSONALIZED MEDICINE 70
110 537 ANTI-CD20 (RITUXIMAB) AS THE SOLE TREATMENT FOR PTLD (POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE) PERSONALIZED MEDICINE 71
111 608 IN VITRO CYTOTOXICITY OF ALLITINIB, AN IRREVERSIBLE ANTI-EGFR AGENT, IN A LARGE PANEL OF HUMAN CANCER CELL LINES: KRAS MUTATION STATUS AS A PREDICTIVE BIOMARKER PERSONALIZED MEDICINE 72
112 614 DESENSITIZATION PROTOCOL WITH ANTI CD20 IN A CHILD WITH SECONDARY LYMPHOPROLIFERATIVE DISEASE PERSONALIZED MEDICINE 73
113 646 WEB-BASED REPORTED OUTCOMES MONITORING AMONG FILIPINO CANCER PATIENTS: A CROSS-SECTIONAL ANAYLSIS OF NEEDS, ACCEPTANCE AND READINESS PERSONALIZED MEDICINE 74
114 656 ISSUES OF GENETIC MODIFICATION IN HUMAN EMBRYO AND ITS FUTURE ORIENTATION PERSONALIZED MEDICINE 75
POSTER SESSION 4
Date: April 27th / Place: POSTER AREA
Time of the session: 1:00pm – 5:30pm / Time of the presentation: 3:30pm – 4:00pm
115 32 CIRCULATORY MEDIASTINAL VACUUM DRAINAGE THERAPY AND ENDOSCOPIC BIOMEDICAL FIBRIN GLUE OCCLUSION: TWO INDIVIDUALIZED METHODS FOR ANASTOMOTIC LEAKAGE AFTER ESOPHAGEAL RESECTION GASTROINTESTINAL 01
116 39 ROLE OF PROBE-BASED CONFOCAL LASER ENDOMICROSCOPY TARGET BIOPSY FOR THE MOLECULAR AND HISTOPATHOLOGICAL STUDY OF GASTRIC CANCER GASTROINTESTINAL 02
117 61 COMBINATION TREATMENT WITH TRANSCATHETERARTERIAL CHEMOEMBOLIZATION AND CRYOABLATION FOR UNRESECTABLE PRIMARY LIVER CANCER WITH TUMOR SIZE >5CM GASTROINTESTINAL 03
118 68 A NOVEL SYSTEMIC INFLAMMATION RESPONSE INDEX (SIRI) FOR PREDICTING THE RESPONSE OF PANCREATIC CANCER TO CHEMOTHERAPY GASTROINTESTINAL 04
119 78 RESPONSE EVALUATION IN ESOPHAGEAL CANCERS, OF NEOADJUVANT CHEMOTHERAPY USING RECIST CRITERIA ON MDCT AND TO CORRELATE IMAGING RESPONSE WITH HISTOPATHOLOGY SEEN IN POSTOPERATIVE SPECIMEN GASTROINTESTINAL 05
120 89 EXPRESSION OF PROGRAMMED CELL DEATH LIGAND 1 (PDL1) AND XIAP IN CHINESE ESOPHAGUS SQUAMOUS CELL CARCINOMA PATIENTS GASTROINTESTINAL 06
121 94 COMPARISON OF SURGERY PLUS CHEMOTHERAPY AND PALLIATIVE CHEMOTHERAPY FOR ADVANCED GASTRIC CANCER WITH SYNCHRONOUS OVARIAN METASTASES GASTROINTESTINAL 07
122 95 SAFETY AND EFFICACY OF S-1 IN ADVANCED HEPATOCELLULAR CARCINOMA GASTROINTESTINAL 08
123 107 EVALUATION OF TUMOR MET AND HER2 EXPRESSION IN PRIMARY AND METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION (G/GEJ) CANCER GASTROINTESTINAL 09
124 142 PROGNOSTIC FACTORS AND CLINICAL CHARACTERISTICS FOR HEPATOCELLULAR CARCINOMA PATIENTS WITH BENIGN ENLARGED PERIHEPATIC LYMPH NODES: A SINGLE-CENTER EXPERIENCE FROM CHINA GASTROINTESTINAL 10
125 144 ANALYSIS OF PROGNOSTIC FACTORS FOR CENTRALLY LOCATED HEPATOCELLULAR CARCINOMA: HIGH RISK, MID RISK, AND LOW RISK:A PILOT STUDY IN A SINGLE CHINESE INSTITUTE GASTROINTESTINAL 11
126 160 ALDH STEM CELLS ARE PREDICTIVE OF SURVIVAL IN PATIENTS WITH PANCREATIC ADENOCARCINOMA TREATED WITH ADJUVANT CHEMORADIATION GASTROINTESTINAL 12
127 163 A IDENTIFICATION OF A HIGHLY RECURRENT C18ORF8-NEDD4L GENE FUSION IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA GASTROINTESTINAL 13
128 179 EXPRESSION AND RELEVANCE OF THE IMPACT PROTEIN IN PANCREATIC CANCER GASTROINTESTINAL 14
129 183 TERT INCREASED TRANSCRIPTIONAL ACTIVITY AND ONCOGENIC TERT PROMOTER MUTATIONS IN GIST. GASTROINTESTINAL 15
130 201 MICRORNA-506 PLAYS DIFFERENT ROLES IN THE DEVELOPMENT AND PROGRESSION OF PANCREATIC DUCTAL ADENOCARCINOMA GASTROINTESTINAL 16
131 212 EVALUATION OF CHEMOSENSITIVITY FOR PATIENTS WITH ADVANCED GASTRIC CANCER BY COLLAGEN GEL DROPLET EMBEDDED CULTURE DRUG SENSITIVITY TEST (CD-DST) AND ITS CORRELATION WITH CLINICOPATHOLOGICAL CHARACTERISTICS GASTROINTESTINAL 17
132 216 THE RELATIONSHIP OF SURVIVAL WITH PATHOLOGIC FACTORS IN ELDERLY GASTRIC CANCER PATIENTS(≥70 YEARS) GASTROINTESTINAL 18
133 217 HYPERMETHYLATION AT THE NDRG4 CPG ISLAND IS ASSOCIATED WITH THE RISK OF GASTRIC CANCER GASTROINTESTINAL 19
134 229 PROGNOSTIC VALUE OF P53 FOR COLORECTAL CANCER AFTER SURGICAL RESECTION OF PULMONARY METASTASES GASTROINTESTINAL 20
135 230 METHYLATION OF CPG ISLANDS IN THE PROMOTER REGIONS OF P16, HMLH1 AND CDH1 GENES IN PATIENTS WITH GASTRIC CANCER GASTROINTESTINAL 21
136 243 ADVANCED HEPATOPANCREATICOBILIARY CANCER RELATED MALIGNANT BILIARY OBSTRUCTION GASTROINTESTINAL 22
137 272 THE CORRELATION OF P53 AND P16 EXPRESSIONS AND ESOPHAGEAL CANCER PATIENTS ONE-YEAR SURVIVAL GASTROINTESTINAL 23
138 285 TRPV2 AMPLIFICATION IN GASTRIC ADENOCARCINOMA GASTROINTESTINAL 24
139 286 THE USE OF GASTRIC WASHES FOR THE IDENTIFICATION OF DNA MUTATIONS IN GASTRIC CANCER: IMPLICATIONS FOR LIQUID-BIOPSY AND PATIENT FOLLOW-UP GASTROINTESTINAL 25
140 289 REG4 ACTIVATES THE MAPK-BIM-CASPASE3 SIGNALING PATHWAY IN 5-FLUOROURACIL RESISTANT GASTRIC CANCER GASTROINTESTINAL 26
141 348 DETECTION HIGH-RISK HPV DNA IN CHAGASIC MEGAESOPHAGUS WITH AND WITHOUT CANCER GASTROINTESTINAL 27
142 412 POSTGASTRECTOMY REDUCED ACUITY VISUAL WITH THIAMINE DEFICIENCY AND ALCOHOL ABUSE GASTROINTESTINAL 28
143 483 EVALUATION OF HELICOBACTER PYLORI IN PERUVIAN RELATIVES OF GASTRIC CANCER PATIENTS GASTROINTESTINAL 29
144 499 ABLATING CHALLENGING LIVER LESIONS: HOW TO GET THERE? GASTROINTESTINAL 30
145 509 EPHB6 RECEPTOR NEGATIVELY REGULATES CHEMOTHERAPY SENSITIVITY AND GASTRIC CANCER CELL GROWTH BY SUPPRESSING ERK-MEDIATED BCL-2 EXPRESSION GASTROINTESTINAL 31
146 512 ANALYSIS OF THE INDICATIONS OF PARAMAGNETIC HEPATOBILIARY CONTRAST AGENT (GD-DTPA-EOD) ON MRI AT A CANCER CENTER. GASTROINTESTINAL 32
147 513 ATYPICAL PATTERNS OF LIVER LESIONS ON MRI WITH PARAMAGNETIC HEPATO-SPECIFIC CONTRAST AGENT (GD-DTPA-EOD). GASTROINTESTINAL 33
148 529 VIRTUAL GASTROSCOPY ON GASTRIC CANCER STAGING GASTROINTESTINAL 34
149 532 COMBINATION THERAPIES IN THE MANAGEMENT OF LARGE (≥ 5 CM) HEPATOCELLULAR CARCINOMA: MICROWAVE ABLATION IMMEDIATELY FOLLOWED BY TRANSARTERIAL CHEMOEMBOLIZATION GASTROINTESTINAL 35
150 564 COULD ANTISENSE OLIGONUCLEOTIDES TARGETED TO K-RAS INHIBIT THE TUMOR GROWTH, INVASIVENESS AND EXPRESSION OF MMP-2 AND MMP-9 IN VITRO AND IN VIVO IN HAMSTER EXPERIMENTAL PANCREATIC CÂNCER MODEL? GASTROINTESTINAL 36
151 600 DESMOPLASTIC SMALL ROUND CELL TUMOR: CASE REPORT GASTROINTESTINAL 37
152 610 THE ANALYSIS OF ADVERSE EVENTS IN ENDOSCOPIC SUBMUCOSAL DISSECTION COMPARED WITH ENDOSCOPIC MUCOSAL RESECTION IN ERLY GASTRIC CANCER. GASTROINTESTINAL 38
153 615 ASYMPTOMATIC INTESTINAL PNEUMATOSIS IN ONCOLOGIC PATIENTS GASTROINTESTINAL 39
154 629 CYTOTOXIC ACTIVITY OF ANTITUMOR COMPOUND E-2-BENZO[D]THIAZOLE INDUCES APOPTOSIS AND INHIBITS MIGRATION IN DIFFUSE TYPE GASTRIC CANCER CELL LINE. GASTROINTESTINAL 40
155 631 GREEN TEA EXTRACT COULD INHIBIT THE TUMOR GROWTH AND INVASIVENESS OF 5-FU AND MMC-RESISTANT METASTATIC AND REMETASTATIC CELL LINES IN A HAMSTER PANCREATIC CANCER MODEL GASTROINTESTINAL 41
156 636 THE ANALYSIS OF ADVERSE EVENTS IN ENDOSCOPIC SUBMUCOSAL DISSECTION COMPARED WITH ENDOSCOPIC MUCOSAL RESECTION IN EARLY GASTRIC CANCER. GASTROINTESTINAL 42
157 642 GALLBLADDER CARCINOMA: WHICH IS THE BEST METHOD TO DIAGNOSIS IN PATIENTS WITH ASYMPTOMATIC GALLBLADDER POLYPS? GASTROINTESTINAL 43
158 647 FACTORS INFLUENCING KI67 CALCULATION IN NEUROENDOCRINE TUMORS GASTROINTESTINAL 44
159 657 NIPPED-B HOMOLOG INCREASES THE SENSITIVITY OF CISPLATIN TO ESCC CELLS THROUGH THE HISTONE DEACETYLATION-DEPENDENT UPREGULATION OF PUMA. GASTROINTESTINAL 45
160 93 H446 CELL GROWTH INHIBITION BY SONODYNAMIC THERAPY USING DVDMS LUNG 46
161 109 THE ANALYSIS OF INCIDENTAL RECEIPT OF BETA-BLOCKER MEDICINE AND OVERALL SURVIVAL OUTCOME AMONG PATIENTS WITH INOPERABLE NSCLC LUNG 47
162 127 FARNESOID X RECEPTOR PROMOTES METASTASIS OF NON-SMALL CELL LUNG CANCER BY TRANSCRIPTIONALLY ACTIVATING MMP-9 LUNG 48
163 162 PROGNOSTIC GENE SIGNATURES FOR LUNG ADENOCARCINOMA USING DIGITAL MULTIPLEXED GENE EXPRESSION IN FORMALIN-FIXED PARAFFIN EMBEDDED TISSUE LUNG 49
164 197 PREDICTING PATHOLOGICAL EFFECTS USING THE TUMOR VOLUME REDUCTION RATE AFTER INDUCTION CHEMORADIOTHERAPY IN LOCALLY ADVANCED NON-SMALL-CELL LUNG CANCER LUNG 50
165 209 COMPARATIVE STUDY OF PLAIN AND CONTRAST CT SCAN OF THORAX TO DETECT PULMONARY PARENCHYMAL METASTASES IN PATIENTS OF BONE AND SOFT TISSUE SARCOMAS. LUNG 51
166 210 SERUM LEVEL OF INTERLEUKIN-6 IN PATIENTS WITH NON-SMALL CELL LUNG CANCER LUNG 52
167 253 DIAGNOSTIC VALUE OF PET / CT COMBINED WITH HRCT FOR THE PURE GROUND-GLASS NODULES LUNG 53
168 255 LACK OF BAP1 NUCLEAR STAINING MAY HELP IDENTIFY MESOTHELIOMA FROM OTHER MALIGNANCIES WITH SIMILAR MORPHOLOGY LUNG 54
169 300 THE CORRELATIVE STUDY BETWEEN EFFICACY OF PEMETREXED COMBINED PLATINUM CHEMOTHERAPY AND POLYMORPHISM OF TYMS、GSTP1 GENE IN ADVANCED NON-SMALL CELL LUNG CANCER LUNG 55
170 324 RAC1 OVEREXPRESSION IS CORRELATED WITH EPITHELIAL-MESENCHYMAL TRANSITION AND PREDICTS POOR PROGNOSIS OF NON-SMALL CELL LUNG CANCER LUNG 56
171 335 A NOMOGRAM TO PREDICT BRAIN METASTASES OF RESECTED NON-SMALL CELL LUNG CANCER PATIENTS LUNG 57
172 344 EXPRESSION OF VEGF IN NON-SMALL CELL LUNG CANCER AND ITS CORRELATION WITH PATHOLOGICAL CHARACTERISTICS LUNG 58
173 347 CYTOKINE-INDUCED KILLER(CIK) AS AN EFFECTIVE ADJUVANT THERAPY IN COMBINATION WITH CONVENTIONAL TREATMENTS IN NON-SMALL-CELL LUNG CANCER(NSCLC) LUNG 59
174 360 MAMMALIAN EPS15 HOMOLOGY DOMAIN 1 PROMOTES METASTASIS IN NON-SMALL CELL LUNG CANCER LUNG 60
175 382 PLASMA THIOREDOXIN REDUCTASE 1 IS A POTENTIAL DIAGNOSTIC BIOMARKER FOR NON-SMALL CELL LUNG CANCE LUNG 61
176 444 CT-GUIDED BIOPSY OF SMALL PULMONARY SUBSOLID LESION: ACCURACY AND COMPLICATIONS LUNG 62
177 457 MUTATION DETECTION IN CIRCULATING FREE DNA (CFDNA) USING A TARGETED NEXT GENERATION SEQUENCING PLATFORM IN LUNG CANCER PATIENTS. LUNG 63
178 458 SAFETY IN MEDIASTINUM PERCUTANEOUS PROCEDURES. COMPILATION OF MAIN ACCESS ROUTES LUNG 64
179 495 PHARMACOLOGICAL MANIPUATION OF P53 FAMILY MEMBERS TO TREAT LUNG CANCER CELLS WITH P53 LOST OR MUTATATIONS LUNG 65
180 526 ANALYSIS OF CHEST COMPUTED ANGIOTOMOGRAPHY EXAMS TO CONFIRM PULMONARY EMBOLISM PERFORMED AT THE EMERGENCY ROOM IN A PRIVATE ONCOLOGIC HOSPITAL IN SÃO PAULO. LUNG 66
181 547 MODIFIED COAXIAL TECHNIQUE AS AN OPTION IN CORE BIOPSIES OF CHALLENGING SMALL MEDIASTINAL LESIONS LOCATED NEAR THE LARGE VESSELS: THE “MARSHMALLOW” TECHNIQUE. LUNG 67
182 553 PERCUTANEOUS ACETABULOPLASTY WITH BALLOON AND CEMENT LUNG 68
183 596 THE ROLE OF ENDOBRONCHIAL ULTRASOUND COMBINED WITH TRANSBRONCHIAL NEEDLE ASPIRATION (EBUS-TBNA) IN THE DIAGNOSIS OF MEDIASTINAL LESIONS LUNG 69
184 625 PERCUTANEOUS CT-GUIDED BIOPSY (PCTGB) OF SMALL (< 2CM) SUBSOLID LESIONS IS CHALLENGING; BUT SAFE AND ACCURATE LUNG 70
185 663 CONCORDANCE BETWEEN IMMUNOHISTOCHEMISTRY (CLONE 5A4), ALK TESTING (CLONE D5F3-VENTANA®) AND FISH (VYSIS) IN PATIENTS WITH ADVANCED-STAGE LUNG ADENOCARCINOMA WITHOUT EGFR, KRAS OR BRAF MUTATIONS. LUNG 71
186 180 THE EXPRESSION OF MULTIDRUG RESISTANCE PROTEIN-1 IN CTCS IS A PREDICTOR OF FAILURE TO IRINOTECAN-BASED CHEMOTHERAPY IN METASTATIC COLORECTAL CANCER LIQUID BIOPSY – PROGNOSTIC AND TREATMENT RESPONSE 72
187 188 DETECTION OF ERCC1 AND MRP-7 IN CIRCULATING TUMOR MICROEMBOLI FROM PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA AND THEIR RELATION WITH PROGRESSION FREE SURVIVAL LIQUID BIOPSY – PROGNOSTIC AND TREATMENT RESPONSE 73
188 74
189 403 RENAL FUNCTION OF PATIENTS CANCER WITH DIABETES TYPE 1 AND 2 THAT WERE SUBJECT TO COMPUTED TOMOGRAPHY AFTER INJECTION OF IODINATED CONTRAST. DIAGNOSTIC IMAGING 75
190 639 IMPROVED CLINICAL DECISION MAKING THROUGH STANDARDIZED CAPTURE AND ANALYSIS OF IMAGING DATA DIAGNOSTIC IMAGING 76
POSTER SESSION 5
Date: April 28th / Place: POSTER AREA
Time of the session: 8:00am – 12:30pm / Time of the presentation: 10:10am – 10:40am
191 447 ADVANCING WOMEN FACULTY CAREERS AT THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER – AND BEYOND ANESTESIOLOGY 01
192 29 THE RELATIONSHIP BETWEEN CIRCUMCISION AND HUMAN PAPILLOMAVIRUS INFECTION CANCER PREVENTION AND EARLY DIAGNOSIS 02
193 147 ASSOCIATION BETWEEN INTRAVAGINAL CLEANSING AND REDUCED CERVICO-VAGINAL HUMAN PAPILLOMAVIRUS INFECTION AMONG FEMALE SEX WORKERS IN CAMBODIA CANCER PREVENTION AND EARLY DIAGNOSIS 03
194 219 AN ANALYZE OF ONE DECADE OF SKIN CANCER PREVENTION PROGRAM USING A MOBILE UNIT CANCER PREVENTION AND EARLY DIAGNOSIS 04
195 349 BRUSH CYTOLOGY ANALYSIS FOR THE DIAGNOSIS OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA CANCER PREVENTION AND EARLY DIAGNOSIS 05
196 398 THE VARIATIONS OF T-LYMPHOCYTES IN HEPATOCELLULAR CARCINOMA INDUCED BY DIETHYLNITROSAMINE IN SD RAT MODEL CANCER PREVENTION AND EARLY DIAGNOSIS 06
197 401 METHYLATION PROFILE OF GENES IN PRECURSOR LESIONS OF CERVICAL CANCER CANCER PREVENTION AND EARLY DIAGNOSIS 07
198 451 EFFECTIVE DOSE ASSESSMENT USED IN CANCER PATIENTS THE PROTOCOL GASTROSCOPY VIRTUAL IN COMPUTED TOMOGRAPHY. CANCER PREVENTION AND EARLY DIAGNOSIS 08
199 462 THE EFFECTIVE DOSE OF THORAX LOW DOSE PROTOCOL ASSESSMENT COMPUTED TOMOGRAPHY FOR SCREENNING WITH LUNG CANCER COMPARED WITH THORAX ROUTINE EXAMINATION. CANCER PREVENTION AND EARLY DIAGNOSIS 09
200 465 ABERRANT PLASMA LEVELS OF CIRCULATING MIR-21 AND MIR-494 ARE ASSOCIATED WITH A POOR PROGNOSIS IN PATIENTS WITH BREAST CANCER. CANCER PREVENTION AND EARLY DIAGNOSIS 10
201 471 CAN THE SCHOOLING LEVEL BE USED AS PROGNOSTIC FACTOR IN CERVICAL CANCER? CANCER PREVENTION AND EARLY DIAGNOSIS 11
202 504 METHYLATION STATUS ANALYSIS OF PROMOTER REGIONS OF MALM1 AND MALM2 GENES AS SCREENING HIGH-RISK HUMAN PAPILLOMAVIRUS POSITIVE PATIENTS CANCER PREVENTION AND EARLY DIAGNOSIS 12
203 520 ANALYSIS OF RKIP EXPRESSION IN CERVICAL CYTOLOGY SAMPLES AS A MARKER FOR HIGH GRADE CERVICAL INTRAEPITHELIAL NEOPLASIA CANCER PREVENTION AND EARLY DIAGNOSIS 13
204 617 DESCRIPTIVE ANALYSES OF BRCA1/2 MUTATION CARRIERS AT HOSPITAL DE CÂNCER DE BARRETOS CANCER PREVENTION AND EARLY DIAGNOSIS 14
205 624 DESCRIPTIVE ANALYSES OF MMR GERMLINE MUTATION CARRIERS AT HOSPITAL DE CÂNCER DE BARRETOS CANCER PREVENTION AND EARLY DIAGNOSIS 15
206 634 DESCRIPTIVE ANALYSES OF PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS AT HOSPITAL DE CÂNCER DE BARRETOS CANCER PREVENTION AND EARLY DIAGNOSIS 16
207 252 MIR-221TARGETS HMGA2 TO INHIBITBLEOMYCIN-INDUCED PULMONARYFIBROSIS BY REGULATING TGF-Β1/SMAD3 INDUCED EMT CRITICAL CARE 17
208 493 “ONCOLOGIC EMERGENCIES” CRITICAL CARE 18
209 533 RETROSPECTIVE ANALYSIS OF PERCUTANEOUS NEPHROSTOMIES IN CANCER PATIENTS. CRITICAL CARE 19
210 597 SUPERIOR VENA CAVA SYNDROME: 3 CASES, MANY LESSONS LEARNED CRITICAL CARE 20
211 350 BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CHEMOTHERAPY FOR THE ELDERLY PATIENTS WITH ACRC: A SYSTEMATIC REVIEW AND META-ANALYSIS OF COMPARATIVE STUDIES GERIATRIC ONCOLOGY 21
212 159 HYPERBARIC OXYGEN AS THE WAY TO OVERCOME THE PROBLEM OF HYPOXIA-INDUCED PROTECTION OF GLIOBLASTOMA CELLS AGAINST MODIFIED ISOTHIOUREA DERIVATIVE (ZKK-3) NEURO-ONCOLOGY 22
213 265 MICROARRAY ANALYSIS OF POLYSOME ASSOCIATED MRNAS FROM A HUMAN GLIOBLASTOMA REVEALS INTRATUMORAL HETEROGENEITY. NEURO-ONCOLOGY 23
214 299 HIGH MYC PROTEIN EXPRESSION PREDICTS UNFAVORABLE SURVIVAL FOR PRIMARY CENTRAL NERVOUS SYSTEM DIFFUSE LARGE B-CELL LYMPHOMA (PCNS-DLBCL) NEURO-ONCOLOGY 24
215 301 ANTI-NEOPLASTIC POTENTIAL OF BRAZILIAN PLANTS CRUDE EXTRACT ON HUMAN GLIOMA CELL LINES NEURO-ONCOLOGY 25
216 371 LOSS OF MTAP EXPRESSION IS ASSOCIATED WITH POOR PROGNOSIS IN GLIOMA PATIENTS NEURO-ONCOLOGY 26
217 378 ROLE OF WNK2 ON GLIOMA CELLS ENDOCYTOSIS PATHWAY. NEURO-ONCOLOGY 27
218 517 EVALUATION OF COMPUTED TOMOGRAPHY EXAMS OF SKULL PERFORMED IN A HOSPITAL EMERGENCY ONCOLOGICAL. NEURO-ONCOLOGY 28
219 579 MOLECULAR CHARACTERIZATION OF BRAZILIAN IMMORTALIZED GLIOBLASTOMA CELL LINES NEURO-ONCOLOGY 29
220 618 THE ROLE OF STRESS INDUCIBLE PROTEIN 1 IN BRAIN TUMOR ANGIOGENESIS NEURO-ONCOLOGY 30
221 641 METHYLATION OF MGMT IN PERUVIAN CASES OF GLIOBLASTOMA: VALIDATION OF EPIGENETIC TECHNIQUE NEURO-ONCOLOGY 31
222 468 DEVELOPMENT AND IMPLEMENTATION OF A PROGRAM FOR INDIVIDUALS AT HIGH RISK FOR BREAST CANCER AT CLINICA ALEMANA, SANTIAGO CHILE BREAST 32
223 469 BRCA 1-2 FULL GENE SEQUENCE + LARGE REARRANGEMENTS OR PANEL GENETIC TESTING ? CLINICA ALEMANA BREAST CANCER RISK EVALUATION UNIT INITIAL EXPERIENCE. BREAST 33
224 475 GENE PREDICTIVE SIGNATURE ASSOCIATED WITH DUCTAL CARCINOMA IN SITU PROGRESSION TO INVASIVE BREAST CANCER BREAST 34
225 476 MR IMAGING IN EVALUATION OF PAGET DISEASE OF THE BREAST: A PICTORIAL ESSAY BREAST 35
226 477 ANALYSIS OF 159 INDETERMINATE BREAST LESIONS WITH ULTRASOUND ELASTOGRAPHY IN AN ONCOLOGY CENTER BREAST 36
227 485 IMAGING APPEARANCES OF MALE BREAST CANCER: A PICTORIAL ESSAY BREAST 37
228 496 BETTER TIMING OF SURGICAL AXILLARY STAGING FOR HER2-OVEREXPRESSED BREAST CANCER: BEFORE OR AFTER NEOADJUVANT CHEMOTHERAPY (NAC)? BREAST 38
229 503 ASSESSING GENOMIC INSTABILITY AND GLOBAL METHYLATION IN SPORADIC AND HEREDITARY TRIPLE-NEGATIVE BREAST TUMORS BREAST 39
230 516 EXTENSIVE SEARCHING FOR BREAST CANCER SPLICING VARIANTS REVEALED A PROTEIN ISOFORM OF TRIM37 AS A POTENTIAL BIOMARKER WITH CLINICAL RELEVANCE BREAST 40
231 523 GENE EXPRESSION PROFILING OF BREAST CANCER IN LEBANESE WOMEN BREAST 41
232 556 THE INFLUENCE OF INTERNATIONAL STUDIES ON THE REALITY OF SUS IN BRAZIL: SENTINEL LYMPH NODE WITHOUT TRANS-OPERATIVE EXAMINATION BREAST 42
233 561 NIPPLE SPARING MASTECTOMY: CURRENT SCENARIO BREAST 43
234 598 [ROLE OF DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING IN THE DIAGNOSTIC OF BREAST LESIONS] BREAST 44
235 633 RISK OF INVASIVE CARCINOMA AMONG OBESE WOMAN WITH LOBULAR CARCINOMA IN SITU. BREAST 45
236 638 DESORPTION ELECTROSPRAY IONIZATION MASS SPECTROMETRY (DESI-MS) IN BREAST CANCER BREAST 46
237 640 LI-FRAUMENI SYNDROME IN FEMALES WITH EARLY ONSET BREAST CANCER IN A MEXICAN POPULATION. BREAST 47
238 652 ITADE FLAP: A GOOD CHOICE FOR MID-SIZED DEFECTS OF THE CHEST WALL BREAST 48
239 654 BREAST CANCER SCREENING IN DEVELOPING COUNTRIES. A SYSTEMATIC REVIEW. BREAST 49
240 655 EXPRESSION OF MTSS1, RPL37A, HTRA1 AND ITS RELATIONSHIP WITH THE COMPLETE PATHOLOGICAL RESPONSE AND SURVIVAL IN PATIENTS WITH LOCALLY ADVANCED BREAST CARCINOMA SUBMITTED TO NEOADJUVANT CHEMOTHERAPY. BREAST 50
241 666 RS1008805 POLYMORPHISM IN THE CYP19A1 GENE IS ASSOCIATED WITH THE PROGNOSIS OF STAGE I-II AND OPERABLE STAGE III BREAST CANCER BREAST 51
242 667 RS1008805 POLYMORPHISM IN CYP19A1 GENE IS RELATED TO THE EFFICACY OF HORMONE THERAPY IN STAGE I–II AND OPERABLE STAGE III BREAST CANCER BREAST 52
243 668 HIGH CIRCULATING CONCENTRATIONS OF HER2 EXTRACELLULAR DOMAIN (ECD) EXHIBITS A POOR PROGNOSTIC IMPACT ON METASTATIC BREAST CANCER PATIENTS BREAST 53
244 102 CHINESE ONCOLOGISTS’ KNOWLEDGE, ATTITUDES AND PRACTICE TOWARDS PALLIATIVE CARE AND END OF LIFE ISSUES POPULATION SCIENCE & CANCER EPIDEMIOLOGY 54
245 146 MICRORNA PROFILES IN METASTATIC VERSUS NON-METASTATIC SALIVARY MUCOEPIDERMOID CARCINOMA POPULATION SCIENCE & CANCER EPIDEMIOLOGY 55
246 177 SEMEN BANK PROFILE: SPERM CRYOPRESERVATION IS ALWAYS INDICATED FOR PATIENTS UNDERGOING CANCER TREATMENT? POPULATION SCIENCE & CANCER EPIDEMIOLOGY 56
247 178 HOW LONG A SPERM SAMPLE CAN REMAIN CRYOPRESERVED? POPULATION SCIENCE & CANCER EPIDEMIOLOGY 57
248 245 CHARACTERISTICS OF INVASIVE ASPERGILOSIS CASES IN STEM CELL TRANSPLANTATION SCENARIO POPULATION SCIENCE & CANCER EPIDEMIOLOGY 58
249 473 FOOD CONSUMPTION AND HEAD AND NECK CANCER IN THREE BRAZILIAN CAPITALS – INTERCHANGE STUDY POPULATION SCIENCE & CANCER EPIDEMIOLOGY 59
250 488 TRANSLATIONAL NETWORK IN TAIWAN: PREDICTIVE, PREVENTIVE, PERSONALIZED AND PARTICIPATORY CANCER RESEARCH POPULATION SCIENCE & CANCER EPIDEMIOLOGY 60
251 489 THE UNIQUE GENOMIC PREDICTIVE MARKERS FOR TAIWAN HEAD AND NECK CANCERS POPULATION SCIENCE & CANCER EPIDEMIOLOGY 61
252 490 SEARCHING FOR THE CAVEOLIN-1 AND CYCLOOXYGENASE 2 GENOMIC MARKERS FOR KIDNEY, URETER, BLADDER AND PROSTATE CANCERS IN TAIWAN POPULATION SCIENCE & CANCER EPIDEMIOLOGY 62
253 511 ROUTINE ANALYSIS OF BRCA1 AND BRCA2 GENES IN AN ISRAELITE BRAZILIAN HOSPITAL: RESULTS AND PECULIAR CLINICAL FINDINGS POPULATION SCIENCE & CANCER EPIDEMIOLOGY 63
254 542 ANALYSIS OF ‘’HERBAL/ALTERNATIVE MEDICINE‘’ TRIALS SUBMITTED TO CLINICALTRIALS.GOV DATABASE POPULATION SCIENCE & CANCER EPIDEMIOLOGY 64
255 563 AMPUTATIONS IN BONE SARCOMA: WHO? WHY? HOW? POPULATION SCIENCE & CANCER EPIDEMIOLOGY 65
256 603 THE PEDIATRIC ONCOLOGY EXPERIENCE AT HOSPITAL ISRALEITA ALBERT EINSTEIN POPULATION SCIENCE & CANCER EPIDEMIOLOGY 66
257 648 DEVELOPMENT AND VALIDATION OF THE WEB-BASED PATIENT-REPORTED OUTCOMES CAPTURE SYSTEM- NEEDS, ACCEPTANCE AND READINESS ASSESSMENT (WPROCS-NARA) QUESTIONNAIRES POPULATION SCIENCE & CANCER EPIDEMIOLOGY 67
POSTER SESSION 6
Date: April 28th / Place: PAMPAS ROOM
Time of the session: 8:00am – 12:30pm / Time of the presentation: 10:10am – 10:40am
258 124 FACIAL LYMPH NODE INVOLVEMENT AS A PROGNOSTIC FACTOR FOR SURVIVAL IN ORAL CAVITY SQUAMOUS CELL CARCINOMA HEAD & NECK 01
259 170 EXOSOMAL DELIVERY OF MIR-24-3P IMPEDES T-CELL PROLIFERATION AND DIFFERENTIATION BY REPRESSING FGF11 AND CORRELATES WITH PROGNOSIS IN NASOPHARYNGEAL CARCINOMA HEAD & NECK 02
260 187 MULTIPHASE ENHANCEMENT PATTERNS OF METASTATIC CERVICAL NODES ON MULTIDETECTOR COMPUTED TOMOGRAPHY (4D-MDCT) HEAD & NECK 03
261 205 SIGNIFICANCE OF SERUM PHOSPHORUS, AND VITAMIN D IN PAPILLARY THYROID CANCER PATIENTS IN THE EASTERN COASTAL CHINA HEAD & NECK 04
262 208 CLINICOPATHOLOGICAL ANALYSIS OF THYROID NEOPLASMS WITH PREOPERATIVE RECURRENT LARYNGEAL NERVE PALSY IN 80 CASES HEAD & NECK 05
263 226 MIR-320B-TARGETED TRIAP1 PREVENTS MITOCHONDRIA FRAGMENTATION AND APOPTOSIS BY CONTROLLING CYTOCHROME C RELEASE IN NASOPHARYNGEAL CARCINOMA HEAD & NECK 06
264 233 MIR-195 SUPPRESSES THE THYOID CANCER BY TARGETED RAF1 HEAD & NECK 07
265 242 LONG-TERM USE OF NIMOTUZUMAB IN COMBINATION WITH INTENSITY-MODULATED RADIOTHERAPY AND CHEMOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED NASOPHARYNGEAL CARCINOMA:EXPERIENCE OF A SINGLE INSTITUTION HEAD & NECK 08
266 261 THE UTILITY OF MONITORING MICROSURGICAL FLAPS HEAD & NECK 09
267 267 APOPTOTIC SIGNALING IN HUMAN SALIVARY GLAND DEVELOPMENT HEAD & NECK 10
268 268 EPITHELIAL-MESENCHYMAL TRANSITION (EMT) DURING SALIVARY GLAND TUMORIGENESIS: EXPRESSION OF E-CADERIN AND C-KIT HEAD & NECK 11
269 290 WHOLE EXOME SEQUENCING ANALYSIS OF NOTCH PATHWAY GENE MUTATIONS IN SALIVARY MUCOEPIDERMOID CARCINOMAS HEAD & NECK 12
270 331 INTEGRATIVE ANALYSIS OF EXPRESSION AND DNA METHYLATION DATA REVEAL PUTATIVE MOLECULAR DRIVERS IN PAPILLARY THYROID CANCER HEAD & NECK 13
271 338 GLOBAL GENE EXPRESSION PROFILE IN THE PROGRESSION OF ORAL PROLIFERATIVE VERRUCOUS LEUKOPLAKIA. HEAD & NECK 14
272 363 INNOVATIVE PALLIATIVE TREATMENT IN ADVANCED HEAD AND NECK CANCER HEAD & NECK 15
273 375 MIR-451 EXPRESSION IMPACTS KEY BIOLOGICAL PROCESSES THROUGH REGULATION OF PI3K/AKT PATHWAY AND HIGHER THERAPY SENSITIVITY WITH INHIBITOR ANTI-EGFR ALLITINIB IN HUMAN HEAD AND NECK CANCER CELL LINES HEAD & NECK 16
274 377 PROGNOSTIC VALUE OF TUMORAL NK CELLS AND T CELLS SPECIFIC SUBSETS IN PATIENTS WITH ORAL SQUAMOUS CELL CARCINOMA HEAD & NECK 17
275 385 ASSOCIATION OF PIM-1 EXPRESSION WITH TUMOR PROGRESSION AND PATIENTS’ PROGNOSIS IN SALIVARY GLAND ADENOID CYSTIC CARCINOMA HEAD & NECK 18
276 413 RNA-SEQ REVEALS TRANSCRIPTIONAL DIFFERENCES BETWEEN EARLY STAGE METASTATIC AND ADVANCED STAGE NON-METASTATIC ORAL SQUAMOUS CELL CARCINOMAS HEAD & NECK 19
277 472 THE IMPACT OF RAB7 EXPRESSION IN HEAD AND NECK SQUAMOUS CELL CARCINOMA PROGRESSION HEAD & NECK 20
278 480 SECOND AND THIRD TUMORS IN PATIENTS WITH HEAD AND NECK CANCER. HEAD & NECK 21
279 481 UTILITY OF FROZEN SECTION IN THE DIAGNOSIS HEAD & NECK 22
280 486 FREE FLAP RECONSTRUCTION OF HEAD AND NECK DEFECTS AFTER ONCOLOGIC RESECCION IN THE INSTITUTE OF CANCER AMERICAS CLINIC. MEDELLIN COLOMBIA. OUTCOMES IN 50 CASES HEAD & NECK 23
281 502 ALCOHOLIZATION OF METASTATIC CERVICAL LYMPH NODES IN THYROID TUMORS HEAD & NECK 24
282 515 SCREENING OF GENOMIC ALTERATIONS IN HEAD AND NECK CARCINOMAS OF YOUNG PATIENTS BY TOTAL EXOME SEQUENCING. HEAD & NECK 25
283 518 PERCUTANEOUS BIOPSY GUIDED BY CT RETROBULBAR TUMORS : EXPERIENCE OF A CANCER CENTER HEAD & NECK 26
284 545 CT-GUIDED GASTROSTOMY: INICIAL EXPERIENCE IN A BRAZILIAN CANCER CENTER HEAD & NECK 27
285 549 CORE-NEEDLE BIOPSIES OF RETROBULBAR TUMORS: EXPERIENCE IN A BRAZILIAN CANCER CENTER HEAD & NECK 28
286 571 MIRNA GENES REGULATED BY DNA METHYLATION IN PAPILLARY THYROID CARCINOMAS HEAD & NECK 29
287 601 CIRCULATING TUMOR MICROEMBOLI (CTM) AS PROGNOSTIC FACTOR FOR PATIENTS WITH HEAD AND NECK ADVANCED SQUAMOUS CELL CARCINOMA (HNSCC) HEAD & NECK 30
288 613 METHYLATION PROFILE OF FOLLICULAR CELL DERIVED THYROID LESIONS HEAD & NECK 31
289 620 ESTABLISHING A DEDICATED NEURO-ULTRASOUND CLINIC WITHIN THE NEURORADIOLOGY SECTION: THE MD ANDERSON HOUSTON EXPERIENCE WITH COLLABORATION TO PROVIDE SIMILAR SERVICES AT BANNER MD ANDERSON CANCER CENTER IN PHOENIX, ARIZONA. HEAD & NECK 32
290 664 PI3K MUTATIONAL STATUS IN ORAL SQUAMOUS CELL CARCINOMA. HEAD & NECK 33
291 157 OVERALL SURVIVAL AMONG OLDER PATIENTS WITH SOLID TUMORS SURVIVORSHIP 34
292 166 EFFICACY AND TOLERABILITY OF 20MG CONTROLLED-RELEASE OXYCODONE TABLETS IN OPIOID-NAÏVE CANCER PAIN PATIENTS WITH NRS HIGHER THAN 6 SURVIVORSHIP 35
293 251 A CLINICAL PLACEMENT PROGRAM FOR PRIMARY CARE PROFESSIONALS AT A COMPREHENSIVE CANCER CENTRE SURVIVORSHIP 36
294 332 STUDY OF THE QUALITY OF LIFE IN PATIENTS WITH PROSTATE ADENOCARCINOMA COMPARED TO INDIVIDUALS OF THE SAME AGE WITHOUT THIS PATHOLOGY. SURVIVORSHIP 37
295 479 IMPACT OF DELIRIUM ON SYMPTOM DISTRESS AND SURVIVAL OF ADVANCED CANCER PATIENTS PRESENTING TO THE EMERGENCY DEPARTMENT: A PROSPECTIVE RANDOMIZED STUDY SURVIVORSHIP 38
296 522 PERCEPTION OF CURABILITY AMONG ADVANCED CANCER PATIENTS RECEIVING PALLIATIVE CARE AROUND THE WORLD SURVIVORSHIP 39
297 562 BRAZILIAN KNEE TUMOR PROSTHESIS: SURVIVORSHIP ANALYSIS AND OUTCOMES SURVIVORSHIP 40
298 464 A MOBILE PHONE PLATFORM FOR CANCER PATIENT EVALUATION AND FOLLOW UP IN SUBSAHARAN AFRICA SURVIVORSHIP 41